Nuvation Bio Inc.
NUVB · NYSE
Company research
Nuvation Bio Inc. (NYSE: NUVB) is a global oncology biopharmaceutical company headquartered in New York City, founded in 2018 by industry veteran David T. Hung, M.D., who previously founded Medivation Inc., the maker of one of the world's leading prostate cancer medicines. The company is focused on tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, with its lead commercial product IBTROZI™ (taletrectinib), an FDA-approved next-generation ROS1 inhibitor for the treatment of ROS1+ non-small cell lung cancer (NSCLC), which launched in June 2025 and has already treated over 600 patients. Beyond its commercial product, Nuvation Bio maintains a diverse oncology pipeline that includes safusidenib, a brain-penetrant mIDH1 inhibitor in Phase 2 trials for low-grade glioma; NUV-1511, an innovative drug-drug conjugate (DDC) for advanced solid tumors; and NUV-868, a BD2-selective BET inhibitor targeting tumor proliferation. With offices in New York, San Francisco, Boston, and Shanghai, and approximately 273 full-time employees, Nuvation Bio has established itself as a commercially-stage oncology company with a market capitalization of approximately $2 billion.
Research reports
Detailed fundamental valuation work contrasts a discounted cash flow model that suggests Nuvation Bio is significantly undervalued with a price-to-book analysis that points to a more stretched valuation, ultimately framing the stock as attractive but high-risk after a sharp run-up. The report walks through performance metrics, sector comparison, and scenario-driven fair value estimates, emphasizing both upside from oncology catalysts and downside if growth or clinical data disappoint.
StockTelescope · November 8, 2025Nuvation Bio Inc. (NYSE: NUVB) Investment Thesis & Strategic AnalysisThis in-depth “Speculative Buy” report argues that IBTROZI’s best-in-class efficacy profile in ROS1+ NSCLC and early launch traction justify a 12–18 month price target of 7–9 per share, implying substantial upside from then-current levels. It analyzes valuation, cash runway, peak sales scenarios, pipeline assets like safusidenib and NUV-1511, and outlines a clear bull/base/bear framework, highlighting execution risks such as competition from Nuvalent’s zidesamtinib, small niche markets, and high annual cash burn.
AInvest · September 7, 2025Nuvation Bio’s Taletrectinib Data and FDA Review as a Catalyst for Share Price MomentumThis article presents a positive near-term thesis that FDA approval of taletrectinib (IBTROZI) in ROS1+ NSCLC, strong response and intracranial efficacy data, and early launch metrics position Nuvation Bio for significant share price appreciation. It emphasizes robust cash reserves, better‑than‑expected Q2 2025 revenue, a strong‑buy consensus with an average 12‑month price target around 7.80, and pipeline catalysts like the TRUST-III Phase 3 trial, while acknowledging ongoing losses and commercialization risk.